CO6592108A2 - Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular - Google Patents

Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular

Info

Publication number
CO6592108A2
CO6592108A2 CO12140238A CO12140238A CO6592108A2 CO 6592108 A2 CO6592108 A2 CO 6592108A2 CO 12140238 A CO12140238 A CO 12140238A CO 12140238 A CO12140238 A CO 12140238A CO 6592108 A2 CO6592108 A2 CO 6592108A2
Authority
CO
Colombia
Prior art keywords
intraocular pressure
alpha
long duration
reducing effect
adrenergic agonist
Prior art date
Application number
CO12140238A
Other languages
English (en)
Inventor
John E Donello
Daniel W Gil
Mohammed I Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6592108(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6592108A2 publication Critical patent/CO6592108A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para reducir la presión intraocular que comprende administrar una cantidad terapéuticamente eficaz de una composición farmacéutica que comprende 4-bromo-5- (2-imidazólin-2-ilamino)bencimidazol o una de sus sales en el ojo afectado de un paciente, en una dosis única, en el cual el ojo afectado tiene una presión intraocular menor que la presión intraocular basal durante al menos ocho (8) horas.
CO12140238A 2010-01-21 2012-08-17 Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular CO6592108A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21

Publications (1)

Publication Number Publication Date
CO6592108A2 true CO6592108A2 (es) 2013-01-02

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12140238A CO6592108A2 (es) 2010-01-21 2012-08-17 Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular

Country Status (17)

Country Link
US (1) US9889088B2 (es)
EP (1) EP2525793B1 (es)
JP (3) JP2013518051A (es)
KR (1) KR20120125305A (es)
CN (1) CN102770135A (es)
AU (1) AU2011207301A1 (es)
BR (1) BR112012018154A2 (es)
CA (1) CA2787573A1 (es)
CL (1) CL2012002038A1 (es)
CO (1) CO6592108A2 (es)
IL (1) IL221030A0 (es)
MX (1) MX2012008516A (es)
RU (1) RU2012134065A (es)
SG (1) SG182637A1 (es)
TW (1) TW201141477A (es)
WO (1) WO2011091225A2 (es)
ZA (1) ZA201205470B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
EP2734200A1 (en) * 2011-07-22 2014-05-28 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
CA2900671A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
EP3647420B1 (en) 2017-06-27 2023-08-23 The University Of Tokyo Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
TW202233170A (zh) * 2020-11-02 2022-09-01 美商偉視醫療股份有限公司 藥物中的降解化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) * 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6495583B1 (en) * 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2603044A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Alpha-2 adrenergic agonists for the treatment of pain
EP1981852A1 (en) 2006-02-06 2008-10-22 NicOx S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
TW201141477A (en) 2011-12-01
ZA201205470B (en) 2013-05-29
AU2011207301A1 (en) 2012-08-09
CL2012002038A1 (es) 2012-11-16
IL221030A0 (en) 2012-09-24
WO2011091225A2 (en) 2011-07-28
US9889088B2 (en) 2018-02-13
BR112012018154A2 (pt) 2016-04-05
KR20120125305A (ko) 2012-11-14
SG182637A1 (en) 2012-08-30
MX2012008516A (es) 2012-10-15
JP2017125074A (ja) 2017-07-20
CA2787573A1 (en) 2011-07-28
EP2525793B1 (en) 2018-09-05
JP2016026206A (ja) 2016-02-12
RU2012134065A (ru) 2014-02-27
CN102770135A (zh) 2012-11-07
EP2525793A2 (en) 2012-11-28
US20110178145A1 (en) 2011-07-21
JP6466504B2 (ja) 2019-02-06
WO2011091225A3 (en) 2012-05-18
JP2013518051A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
CO6592108A2 (es) Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular
DOP2011000104A (es) Combinacion de una insulina y un agonista de glp-1
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
GT201200217A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
CR20110110A (es) Composicion farmaceutica
ES2721900T3 (es) Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CR20120663A (es) Combinaciones que comprenden antisicóticos atípicos y agonistas taar1
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
CL2015000434A1 (es) Metodo para el tratamiento, prevencion o disminucion de la severidad de una condicion o trastorno no neoplasico de la piel que comprende administrar un compuesto derivado de retinoides; composicion dermica que comprende los derivados de retinoide.
NZ706990A (en) A veterinary method of alleviating noise aversion
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
AR090929A1 (es) Identificacion de la respuesta de un paciente a la administracion del modulador del receptor de s1p
AR085523A1 (es) Mecanismo de establecimiento de dosis y dispositivo de inyeccion

Legal Events

Date Code Title Description
FC Application refused